AtriCure(US:ATRC)2025-04-29 20:00Revenue Performance - First quarter 2025 revenue was $123.6 million, a 13.6% increase year-over-year (14.1% on a constant currency basis) [4] - U.S. revenue reached $101.1 million, up $10.9 million or 12.1% compared to Q1 2024, driven by key product lines [4] - International revenue increased by $3.9 million or 20.8% (23.9% on a constant currency basis) to $22.5 million [4] - Full year 2025 revenue is projected to be approximately $517 million to $527 million [6] Profitability Metrics - Gross profit for Q1 2025 was $92.6 million, with a gross margin of 74.9%, an increase of 27 basis points from Q1 2024 [4] - Adjusted EBITDA for Q1 2025 was $8.8 million, an increase of $6.0 million from the same period in 2024 [5] - Management expects full year 2025 adjusted EBITDA of approximately $44 million to $46 million [6] Net Loss and Adjusted Loss - Basic and diluted net loss per share for Q1 2025 was $0.14, compared to $0.28 for Q1 2024 [4] - The company reported a net loss of $6.7 million for Q1 2025, an improvement of $6.5 million year-over-year [8] - Reported net loss for Q1 2025 was $6,747 million, an improvement from a net loss of $13,269 million in Q1 2024 [25] - Non-GAAP adjusted net loss for Q1 2025 was $6,747 million, compared to $11,907 million in Q1 2024 [25] - Basic and diluted adjusted net loss per share decreased to $0.14 in Q1 2025 from $0.25 in Q1 2024 [25] - Weighted average shares used in computing adjusted net loss per share increased to 47,393 thousand in Q1 2025 from 46,719 thousand in Q1 2024 [25] Market Growth - Significant growth was noted in major geographic markets across key product lines, particularly in appendage management and pain management [4]